Michael Kunz, Marita Kieble, Andrea Espinosa Daudí, Lucas Lauder, Ulrich Laufs, Felix Götzinger, Jasper Boeddinghaus, Gregor Leibundgut, Christoph R Meier, Christian Mueller, Martin Schulz, Felix Mahfoud
{"title":"National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany.","authors":"Michael Kunz, Marita Kieble, Andrea Espinosa Daudí, Lucas Lauder, Ulrich Laufs, Felix Götzinger, Jasper Boeddinghaus, Gregor Leibundgut, Christoph R Meier, Christian Mueller, Martin Schulz, Felix Mahfoud","doi":"10.57187/5371","DOIUrl":"https://doi.org/10.57187/5371","url":null,"abstract":"<p><strong>Study aims: </strong>Prolonged low-dose antithrombotic and anti-inflammatory therapies have been shown to reduce cardiovascular events and are guideline-recommended in patients with coronary artery disease at high ischaemic risk. However, their real-world dispensing patterns at the population level remain insufficiently characterised. This study aimed to quantify national dispensing volumes and compare the use of these therapies in Switzerland and Germany between 2022 and 2024.</p><p><strong>Methods: </strong>We analysed national pharmaceutical delivery data from Switzerland and outpatient prescription data from Germany for low-dose monotherapy products containing aspirin (100 mg), clopidogrel (75 mg), prasugrel (5 mg and 10 mg), ticagrelor (60 mg and 90 mg), rivaroxaban (2.5 mg) and colchicine (0.5 mg in Germany, 1 mg in Switzerland). Drug utilisation was standardised as the number of tablets per 1000 persons per year. This metric reflects population-level exposure: based on epidemiological data indicating a substantial burden of cardiovascular disease and evidence that a relevant proportion of these patients may qualify for intensified long-term preventive therapy, dispensing volumes of long-term antithrombotic and anti-inflammatory therapies might be expected to reach a meaningful fraction of aspirin use (>10%). Values substantially below this illustrative threshold may suggest limited population-level uptake.</p><p><strong>Results: </strong>Aspirin 100 mg was the most frequently dispensed drug in both Switzerland and Germany (both >8000 tablets/1000 persons/year). Clopidogrel ranked second in both countries. Ticagrelor (60 mg and 90 mg) was more frequently dispensed in Switzerland, whereas prasugrel 10 mg was more frequently dispensed in Germany. However, absolute use of both agents remained low (all <500 tablets/1000 persons/year). Rivaroxaban 2.5 mg was the only agent that showed a consistent increase over time (+54.4% Switzerland; +40.4% Germany), although overall dispensing remained modest (538-577 tablets/1000 persons/year). Colchicine use was low in both countries (124-163 tablets/1000 persons/year). Across both countries, the combined dosing-adjusted dispensing volume of intensified long-term antithrombotic and anti-inflammatory therapies was close to or below the illustrative 10% benchmark relative to aspirin use, reaching 10.1% in Germany and 4.5% in Switzerland, suggesting limited population-level uptake, particularly in Switzerland.</p><p><strong>Conclusion: </strong>Despite minor country-specific differences in cardiovascular disease prevalence, the observed dispensing patterns suggest that the population-level uptake of low-dose antithrombotic and anti-inflammatory therapies may be lower than expected when interpreted relative to aspirin.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5371"},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Supplementum 307: Abstracts of the 58th annual meeting of the Swiss Society of Nephrology (Bern, Switzerland, December 3-4, 2026).","authors":"Swiss Society Of Nephrology","doi":"10.57187/5940","DOIUrl":"https://doi.org/10.57187/5940","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 11","pages":"Suppl. 307"},"PeriodicalIF":1.6,"publicationDate":"2026-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Swiss Society Of Medical Oncology, Swiss Society Of Hematology, Swiss Cancer Institute
{"title":"Supplementum 306: Abstracts of the Swiss Oncology and Hematology Congress (SOHC) (Basel, Switzerland, November 18-20, 2026).","authors":"Swiss Society Of Medical Oncology, Swiss Society Of Hematology, Swiss Cancer Institute","doi":"10.57187/5878","DOIUrl":"https://doi.org/10.57187/5878","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 11","pages":"Suppl. 306"},"PeriodicalIF":1.6,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149418068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Death: irreversible or permanent?","authors":"Rainer Beckmann, Georg M Stoffel","doi":"10.57187/5182","DOIUrl":"10.57187/5182","url":null,"abstract":"<p><p>The most recent guidelines for determining brain death restrict diagnostic criteria to the demonstration of a \"permanent\" loss of either brain or cardiopulmonary function. This approach departs from the conventional understanding of \"death\", which is defined by \"irreversibility\" rather than mere \"permanence\". Current guidelines in Canada, the USA and the UK, as well as a draft guideline from Switzerland, do not provide convincing justification for this conceptual shift. By adopting permanence as the operative standard, these guidelines risk undermining the dead donor rule, which requires that organ retrieval occur only after death has been definitively established.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5182"},"PeriodicalIF":1.6,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alan Costa, Reto Lienhard, Florian Tagini, Gilbert Greub, Philippe Temperli, Aline Sedda, Oriane Aebischer, Oscar Marchetti
{"title":"Human granulocytic anaplasmosis acquired in Switzerland: a case report.","authors":"Alan Costa, Reto Lienhard, Florian Tagini, Gilbert Greub, Philippe Temperli, Aline Sedda, Oriane Aebischer, Oscar Marchetti","doi":"10.57187/5479","DOIUrl":"https://doi.org/10.57187/5479","url":null,"abstract":"<p><strong>Background: </strong>Human granulocytic anaplasmosis, caused by Anaplasma phagocytophilum, is a tick-borne disease endemic in North America that is emerging in Europe and may be underdiagnosed in Switzerland.</p><p><strong>Case presentation: </strong>A man in his early seventies receiving methotrexate for ankylosing spondylitis and exposed to ticks presented with a 2-day history of fever, headache and dizziness. Despite empirical broad-spectrum beta-lactam and macrolide therapy, high fever of undetermined origin persisted, and neurological deterioration occurred (somnolence, dysarthria, ataxia, diplopia). Cerebrospinal fluid analysis showed 10 mononuclear cells/µL (normal <5 cells/µL) and protein 476 mg/l (150-450 mg/l). Brain MRI revealed nonspecific leukoencephalopathy. Intravenous doxycycline 100 mg twice daily was empirically initiated on day 7 after symptom onset, resulting in clinical cure within 3 days. Human granulocytic anaplasmosis was retrospectively confirmed by IgG seroconversion against A. phagocytophilum after 6 weeks (8-fold titre increase from <1:64 to 1:512).</p><p><strong>Discussion: </strong>Human granulocytic anaplasmosis represents a diagnostic challenge in non-endemic areas. The human granulocytic anaplasmosis clinical spectrum ranges from mild self-limiting flu-like illness to severe, life-threatening multisystem disease, especially in older immunocompromised patients. Acute-phase diagnosis relies on blood PCR testing. Seroconversion with a 4-fold increase in IgG titre within 2-4 weeks is the gold standard for diagnosis in the convalescent phase. Doxycycline is the first-line antimicrobial therapy.</p><p><strong>Conclusion: </strong>Human granulocytic anaplasmosis is an emerging tick-borne disease which can be acquired in Switzerland. Early diagnostic work-up using blood PCR and empirical doxycycline therapy are key in patients at risk of exposure to ticks who present with severe acute febrile illness without an alternative diagnosis.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5479"},"PeriodicalIF":1.6,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stefanie Lehner, Thierry Chevalley, Michael Dietrich, Sigrid Jehle-Kunz, Gregor Freystaetter
{"title":"Fracture Liaison Services in Switzerland: current status and challenges.","authors":"Stefanie Lehner, Thierry Chevalley, Michael Dietrich, Sigrid Jehle-Kunz, Gregor Freystaetter","doi":"10.57187/5256","DOIUrl":"10.57187/5256","url":null,"abstract":"<p><p>Switzerland is one of the very high-risk countries for osteoporosis. The Fracture Liaison Service is the internationally endorsed model for secondary fracture prevention and for reducing mortality after a person has sustained a fragility fracture. In this article, we describe current Fracture Liaison Service coverage and structure in Switzerland and the challenges Fracture Liaison Services are facing. Good interdisciplinary cooperation, especially with general practitioners, is a key factor. Artificial intelligence (AI) for the detection of vertebral fractures, shared electronic medical records, digital platforms and telemedicine are emerging and evolving approaches to overcome the existing barriers to osteoporosis treatment.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5256"},"PeriodicalIF":1.6,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Flurina Suter, Cornelia Richter, Sarah R Haile, Katharina Staehelin, Matthias Lorez
{"title":"Complete cancer prevalence in Switzerland in 2025: a population-based study using registry data.","authors":"Flurina Suter, Cornelia Richter, Sarah R Haile, Katharina Staehelin, Matthias Lorez","doi":"10.57187/5257","DOIUrl":"https://doi.org/10.57187/5257","url":null,"abstract":"<p><strong>Introduction: </strong>The number of individuals living with a prior cancer diagnosis has increased steadily worldwide over recent decades. This increasing prevalence places substantial demands on healthcare systems to address the diverse healthcare needs of cancer survivors, particularly long-term survivors. The primary objective of this study was to estimate complete cancer prevalence in Switzerland as of the end of 2025 and to examine trends over the past two decades.</p><p><strong>Methods: </strong>Population-based data from the National Agency for Cancer Registration was used, including incidence years 1980-2021 and all primary malignant cancer diagnoses, excluding non-melanoma skin cancer. Complete prevalence was estimated using modelled completeness indexes based on Swiss data for 34 cancer reporting groups and on EUROCARE-6 data for 11 sex-specific cancer reporting groups. For one cancer group, only the Swiss empirical completeness index was available. Average annual percentage changes (AAPC) in cancer prevalence counts were calculated for major cancer types.</p><p><strong>Results: </strong>By the end of 2025, an estimated 242,260 men (5.4% of the male population) and 253,040 women (5.6% of the female population) in Switzerland were living with a previous cancer diagnosis. Among men, 24% were classified as long-term survivors (5-10 years after diagnosis) and 40% as very long-term survivors (>10 years after diagnosis); the corresponding proportions among women were 22% and 49%, respectively. Between 2005 and 2025, cancer prevalence increased annually by 3.6% in men and 3.0% in women, resulting in an almost 2-fold increase in the number of prevalence cases. Both complete and limited-duration prevalence, as well as AAPCs, varied by cancer type and age group.</p><p><strong>Conclusions: </strong>The implemented methodologies provide a basis for regularly updated cancer prevalence estimates in Switzerland. The findings offer essential evidence to support policy-makers and healthcare planners in developing strategies to manage the growing cancer burden and to address the heterogeneous needs of cancer survivor populations.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5257"},"PeriodicalIF":1.6,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Swiss Society For Anaesthesiology And Perioperative Medicine, Swiss Association For Anaesthesia Care
{"title":"Supplementum 305: Abstracts SwissAnaesthesia 2026, joint annual congress of the Swiss Society for Anaesthesiology and Perioperative Medicine and the Swiss Association for Anaesthesia Care (Interlaken, Switzerland, November 5-7, 2026).","authors":"Swiss Society For Anaesthesiology And Perioperative Medicine, Swiss Association For Anaesthesia Care","doi":"10.57187/5885","DOIUrl":"https://doi.org/10.57187/5885","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"305"},"PeriodicalIF":1.6,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Léo König, Beckey Trinh, Barbara Lucchini, Noela Vontobel, Sarah Sigrist, Lia Bally, Philipp Schuetz, Sandrina Bervini, Tinh-Hai Collet, Claudia Cavelti-Weder
{"title":"Insulin therapy with enteral and parenteral nutrition: a consensus statement endorsed by the Swiss Society for Endocrinology and Diabetology and the Swiss Society for Clinical Nutrition and Metabolism.","authors":"Léo König, Beckey Trinh, Barbara Lucchini, Noela Vontobel, Sarah Sigrist, Lia Bally, Philipp Schuetz, Sandrina Bervini, Tinh-Hai Collet, Claudia Cavelti-Weder","doi":"10.57187/5268","DOIUrl":"10.57187/5268","url":null,"abstract":"<p><strong>Background: </strong>Nutritional support with enteral or parenteral nutrition is often required in hospitalised patients and can impair glycaemic control. Despite its clinical importance, practical and uniform recommendations for insulin therapy are lacking.</p><p><strong>Methods: </strong>The Swiss Society for Endocrinology and Diabetology convened an expert panel to develop consensus guidance on insulin therapy for patients receiving enteral or parenteral nutrition. The working group reviewed available evidence, international guidelines and current practice in Swiss hospitals, and harmonised approaches across regions. The resulting statement provides strategies for insulin dosing in intermittent, continuous and bolus enteral nutrition, as well as parenteral nutrition, primarily for inpatient care, but also applicable to home-based nutritional support.</p><p><strong>Recommendations: </strong>The insulin dose depends on the (known or calculated) basal insulin requirement and the carbohydrate content of the enteral or parenteral nutrition bag. For intermittent enteral nutrition (infused over 12-14 hours), intermediate-acting insulin with a duration of action matching the feeding duration is recommended. For continuous enteral nutrition (over 24 hours), long-acting insulin is preferred. When enteral nutrition is administered as boluses (2-3 hours each), short-acting insulin should be injected before each bolus, similar to prandial dosing with meals. For parenteral nutrition, adding short-acting insulin directly to the parenteral nutrition bag is encouraged, as it helps maintain stable glycaemic control without increasing the risk of hypoglycaemia. Across all modalities, correction insulin should be prescribed according to institutional schemes and individualised requirements, with additional units of correction insulin incorporated into the subsequent day's basal and (par)enteral nutrition insulin dose. The statement also provides recommendations for glucose monitoring, safe transitions between regimens, and management of unexpected interruptions in nutritional therapy.</p><p><strong>Conslusions: </strong>This consensus statement, endorsed by the Swiss Society for Endocrinology and Diabetology and the Swiss Society for Clinical Nutrition and Metabolism, represents a nationwide framework for insulin therapy in patients receiving enteral or parenteral nutrition in Switzerland. By standardising insulin use, it aims to enhance safety, reduce glycaemic variability and improve outcomes in hospitalised patients and in those receiving home-based specialised nutritional support.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5268"},"PeriodicalIF":1.6,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Knowledge, attitudes and practices of Swiss reproductive health and paediatrics professionals regarding female genital mutilation/cutting: a cross-sectional study.","authors":"Yara Bazzoun, Christina Marea, Jasmine Abdulcadir","doi":"10.57187/5171","DOIUrl":"https://doi.org/10.57187/5171","url":null,"abstract":"<p><p> STUDY AIMS: Reproductive health and paediatrics professionals play a key role in the prevention and management of female genital mutilation/cutting (FGM/C) and its consequences. While global studies on knowledge, attitudes and practices regarding FGM/C exist, none have specifically focused on these professionals in Switzerland. This study addresses this gap by using a valid, theoretically informed measure to provide new insights into their knowledge and practices regarding FGM/C. The study aimed to identify gaps in knowledge, attitudes, practices and confidence regarding FGM/C among Swiss specialists, to inform training programmes and policy recommendations.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey between August and October 2021. Physicians, nurses and midwives working in the reproductive health and paediatrics departments of the five Swiss University hospitals were invited to participate (convenience sampling). The questionnaire was administered in English, and all participants who had at least B1-level English proficiency and who had ever heard of FGM/C were eligible to participate. The primary outcome was knowledge score on FGM/C, and exploratory outcomes included attitudes, self-reported practices and confidence levels.</p><p><strong>Results: </strong>A total of 127 reproductive health workers and 76 paediatrics workers completed the survey. Mean knowledge scores were 25.7/31 for reproductive health and 19.5/27 for paediatrics workers; the differing denominators reflect the distinct number of knowledge items included in each group's specific questionnaire modules. Knowledge gaps common to both groups included correct identification of WHO FGM/C types (reproductive health: 35-68%; paediatrics: 9-18%), and awareness of surgical treatment options. Reproductive health workers demonstrated low knowledge regarding indications for caesarean in patients with infibulation (66%), while paediatrics workers were less familiar with the Swiss legal context and reporting regulations. While healthcare providers generally condemned the practice of FGM/C and recognised their responsibility to address it with patients, most perceived women with FGM/C as \"victims\" and the communities that practice it as oppressive. Confidence levels were particularly low regarding the visual identification of FGM/C in children and coding capacities.</p><p><strong>Conclusions: </strong>This is the first study to assess specialists' knowledge, attitudes, practices and confidence regarding FGM/C at a national level. It highlights key gaps to address in future training programmes - including both biomedical skills and also bias awareness - with particular attention to inter-regional differences and underscores the need for accessible national and local guidelines to be actively implemented in all hospitals.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"156 ","pages":"5171"},"PeriodicalIF":1.6,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}